[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624883":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":45,"responsibleParty":64,"collaborators":66,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":26,"enrollmentInfo":78,"targetDuration":26,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},{"fullName":5,"class":6},"University of Aarhus","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Surgery group","EXPERIMENTAL","Participants assigned to this arm will undergo subtotal parathyroidectomy performed according to standard surgical practice. The procedure involves removal of the majority of parathyroid tissue with preservation of a small remnant. Intraoperative parathyroid hormone (PTH) measurements will be used to guide the extent of resection, in accordance with standard surgical principles. Surgery will be performed by experienced ear, nose and throat (ENT) surgeons. Participants will receive standard perioperative care and postoperative follow-up.",[13],"Procedure: Subtotal Parathyroidectomy",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","ACTIVE_COMPARATOR","Participants assigned to this arm will receive conservative management according to standard clinical practice. This includes regular clinical follow-up and biochemical monitoring of calcium, phosphate, and parathyroid hormone levels. Medical treatment, such as calcium or vitamin D supplementation and\u002For calcimimetic therapy, may be initiated or adjusted at the discretion of the treating physician. No parathyroid surgery will be performed during the 12-month study period.",[19],"Other: Conservative Management",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Subtotal Parathyroidectomy","Subtotal parathyroidectomy performed according to standard surgical practice. The procedure involves removal of the majority of parathyroid tissue with preservation of a small remnant. Intraoperative parathyroid hormone (PTH) measurements are used to guide the extent of resection. Standard perioperative care and postoperative follow-up are provided.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Conservative Management","Conservative management according to standard clinical practice, including regular clinical follow-up and biochemical monitoring of calcium, phosphate, and parathyroid hormone levels. Medical treatment, such as calcium or vitamin D supplementation and\u002For calcimimetic therapy, may be initiated or adjusted based on clinical judgment.",[15],[32],{"name":33,"affiliation":34,"role":35},"Hanne S Jørgensen, MD, PhD","Department of Nephrology, Aarhus University Hospital","PRINCIPAL_INVESTIGATOR",[37,41],{"name":33,"role":38,"phone":39,"phoneExt":26,"email":40},"CONTACT","+45 51 41 35 41","hsjorgensen@clin.au.dk",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Amal Derai, MD","+45 51 36 03 80","amader@rm.dk",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Departement of Nephrology, Aarhus University hospital","RECRUITING","Aarhus","Central Jutland","8200","Denmark","DK",{"type":55,"coordinates":56},"Point",[57,58],10.21076,56.15674,{"lat":58,"lon":57},[61,62],{"name":33,"role":38,"phone":39,"phoneExt":26,"email":40},{"name":63,"role":38,"phone":43,"phoneExt":26,"email":44},"Amal Derai, MD, PhD",{"type":65,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[67],{"name":5,"class":6},"100624883","parathyroidectomy-after-kidney-transplantation-100624883",false,"NCT07415421","Parathyroidectomy After Kidney Transplantation","Subtotal Parathyroidectomy for the Treatment of Persistent Hyperparathyroidism After Kidney Transplantation","Para-KiT","Inclusion criteria\n\n* Age \\> 18 years and legally competent and able to understand spoken and written Danish\n* Kidney transplantation ≥6 months prior (no upper limit of time after transplantation)\n* Stable kidney graft function, defined as estimated GFR ≥ 30 ml\u002Fmin\u002F1.73m3\n* On minimum two separate biochemical measurements:\n\nPTH \\> upper normal limit of assay and\n\n* serum ionized calcium ≥1.33 mmol\u002FL or\n* serum total calcium ≥2.60 mmol\u002FL or\n* serum phosphate ≤0.60 mmol\u002FL despite sufficient dietary intake\n\nwith measurements obtained within\n\n* 3 months in patients 6-12 months post-transplant\n* 6 months in patients \\>12 months post-transplant\n\nand not attributable to calcium supplementation or treatment with thiazide diuretics or lithium.\n\nExclusion criteria\n\n* Inability to provide written, informed consent\n* Current anti-resorptive therapy (bisphosphonate, denosumab)\n* Current bone anabolic therapy (teriparatide, romosozumab)\n* Previous surgical parathyroidectomy\n* Not considered fit for surgery (including pregnancy)\n* Ionized calcium ≥1.50 mmol\u002FL or albumin-corrected calcium ≥3.00 mmol\u002FL despite discontinuation of calcium supplements.","ALL","18 Years",{"count":79,"type":80},85,"ESTIMATED","INTERVENTIONAL",[83],"NA","This study aims to clarify whether surgical treatment of persistent hyperparathyroidism after kidney transplantation offers clinically meaningful benefits compared with a conservative treatment strategy.\n\nKidney transplant recipients (\\>6 mo after transplantation) with persistent hyperparathyroidism (elevated PTH and either hypercalcemia or hypophosphatemia) will be randomized in a 1:1 ratio to either subtotal parathyroidectomy or conservative management according to standard clinical practice. The study is conducted as an open-label, randomized controlled pilot trial with a 12-month follow-up period.\n\nOutcomes include bone density, physical function, quality of life and symptom burden.",[86,87],"Hyperparathyroidism","Kidney Transplantation Recipients",[89,90,91,92,93,94,95],"Persistent hyperparathyroidism","Kidney transplant recipients","Parathyroidectomy","Bone mineral density","Muscle function","Quality of life","Randomized controlled trial","2026-06-25",{"date":98,"type":99},"2026-06-26","ACTUAL",{"date":101,"type":99},"2026-03-03",{"date":103,"type":80},"2030-12-31",{"name":105,"class":6},"Aarhus University Hospital",1]